Gastrointestinal Cancer News

CHICAGO — Pazopanib was associated with a significant improvement in PFS compared with placebo in patients with progressive carcinoid tumors, according to phase 2 data at the ASCO Annual Meeting.

Lost earnings from cancer deaths in the United States totaled more than $94 billion in 2015, with wide variations in economic burden across states, according to study results published in JAMA Oncology.

AFPc³³²T in Advanced HCC is a phase 1, open-label, first-in-human clinical trial to evaluate the safety and anti-tumor activity of genetically engineered affinity-enhanced autologous T cells that target the HLA-A*02-restricted alpha-fetoprotein peptide for the treatment of adults with relapsed or refractory HCC.

Phase 2 trial evaluating the efficacy of a non-myeloablative lymphodepleting preparative regimen followed by infusion of autologous tumor-infiltrating lymphocytes and high-dose aldesleukin (Proleukin; Boehringer Ingelheim, Prometheus Laboratories) in patients with locally advanced, recurrent, or metastatic biliary tract cancer.

In a large cohort of Korean adults, the cumulative incidence rate for pancreatic cancer increased with fasting glucose level, even in people without diabetes, according to database analysis published in The Journal of Clinical Endocrinology & Metabolism.

The phrase “art of medicine” underscores the fact that the practice of the profession is open to interpretation within the guidelines of scientific principles.

The FDA granted breakthrough therapy designation to pembrolizumab in combination with lenvatinib as first-line treatment for patients with advanced unresectable hepatocellular carcinoma who are not able to receive locoregional treatment.

Colorectal cancer diagnoses among individuals aged younger than 50 years continued to increase in the United States over the past decade, according to results of a retrospective study published in Cancer.

Healio.com and HemOnc Today provide a compilation of seven important updates in immuno-oncology from the past month.

More than half of patients with pancreatic adenocarcinoma showed clinical responses when treated with an investigational multiantigen-specific T-cell therapy, according to the results of an ongoing phase 1 clinical trial presented at the ACCR’s Immune Cell Therapies for Cancer conference in San Francisco.